Belatacept is currently involved in a pilot, phase I/II clinical trial (ATTAIN) to desensitize kidney transplant candidates with calculated Panel Reactive Antibody (cPRA) values ≥ 99.9%, together with daratumumab, a CD38 monoclonal antibody used in multiple myeloma. This evidence concerns the gene CD38 and plasma cell myeloma.